publication . Other literature type . Article . 2020

Rationale for the use of sphingosine analogues in COVID-19 patients

Deborah R. Tasat; Juan Sebastian Yakisich;
Open Access English
  • Published: 03 Nov 2020
  • Publisher: Royal College of Physicians
Despite the recent announcement of promising drug candidates to treat COVID-19, there is currently no effective antiviral drug or vaccine. There is strong evidence that acute lung injury/acute respiratory distress syndrome (ALI/ARDS), likely triggered by a cytokine storm, is responsible for the severity of disease seen in COVID-19 patients. In support of this hypothesis, pilot studies using IL-6 receptor inhibitors such as tocilizumab have shown promising results. Therefore, the use of drugs or cocktails of drugs with broader ability to inhibit these cytokine receptors is likely to be effective. In this article, we propose the use of sphingosine analogues, which...
Persistent Identifiers
free text keywords: COVID-19 rapid report, General Medicine, Antiviral drug, medicine.drug_class, medicine, ARDS, medicine.disease, Lung injury, Tocilizumab, chemistry.chemical_compound, chemistry, business.industry, business, Immunology, Sphingosine, Drug, media_common.quotation_subject, media_common, Cytokine storm, Fingolimod, medicine.drug
Related Organizations
  • COVID-19
Any information missing or wrong?Report an Issue